Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia

Experimental Hematology

Volumn 42, Issue 2, 2014, Pages 126-136.e1

  Maffei, Rossana ^a   Fiorcari, Stefania ^a   Bulgarelli, Jenny ^a   Rizzotto, Lara ^b   Martinelli, Silvia ^a   Rigolin, Gian Matteo ^b   Debbia, Giulia ^a   Castelli, Ilaria ^a   Bonacorsi, Goretta ^a   Santachiara, Rita ^a   Forconi, Francesco ^c,d   Rossi, Davide ^e   Laurenti, Luca ^f   Palumbo, Giuseppe A ^g   Vallisa, Daniele ^h   Cuneo, Antonio ^b   Gaidano, Gianluca ^e   Luppi, Mario ^a   Marasca, Roberto ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h Hospital of Piacenza   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 2; FIBROBLAST GROWTH FACTOR 2; LENALIDOMIDE; THROMBOSPONDIN 1; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CAPILLARY DENSITY; CELL INTERACTION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM; ENDOTHELIUM CELL; FEMALE; HUMAN; IN VITRO STUDY; LEUKEMIA CELL; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; CELL SURVIVAL; ENDOTHELIAL CELLS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; THALIDOMIDE;

EID: 84896727745     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.10.007     Document Type: Article

References (50)

1. Meads M.B., Hazlehurst L.A., Dalton W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14:2519-2526.
2. Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96:2655-2663.
3. Ding W., Nowakowski G.S., Knox T.R., et al. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol 2009, 147:471-483.
4. Maffei R., Fiorcari S., Bulgarelli J., et al. Physical contact with endothelial cells through beta1- and beta2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. Haematologica 2012, 97:952-960.
5. Pedersen I.M., Kitada S., Leoni L.M., et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002, 100:1795-1801.
6. Maffei R., Martinelli S., Santachiara R., et al. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood 2010, 116:584-592.
7. Peterson L., Kini A.R. Angiogenesis is increased in B-cell chronic lymphocytic leukemia. Blood 2001, 97:2529.
8. Molica S., Vacca A., Ribatti D., et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 2002, 100:3344-3351.
9. McCabe D., Bacon L., O'Regan K., Condron C., O'Donnell J.R., Murphy P.T. CD38 expression on B-cell chronic lymphocytic leukemic cells is strongly correlated with vascular endothelial growth factor expression. Leukemia 2004, 18:649-650.
10. Huttmann A., Klein-Hitpass L., Thomale J., et al. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. Leukemia 2006, 20:1774-1782.
11. Cols M., Barra C.M., He B., et al. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. J Immunol 2012, 188:6071-6083.
12. Kurtova A.V., Balakrishnan K., Chen R., et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009, 114:4441-4450.
13. Martinelli S., Maffei R., Castelli I., et al. Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis. Leuk Res 2008, 32:593-597.
14. Shanafelt T.D., Kay N.E. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol 2006, 33:174-185.
15. Maffei R., Martinelli S., Castelli I., et al. Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. Leukemia Res 2010, 34:312-321.
16. Buggins A.G., Pepper C., Patten P.E., et al. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res 2010, 70:7523-7533.
17. Chanan-Khan A., Miller K.C., Musial L., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006, 24:5343-5349.
18. Ferrajoli A., Lee B.N., Schlette E.J., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111:5291-5297.
19. Badoux X.C., Keating M.J., Wen S., et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011, 118:3489-3498.
20. Chen C.I., Bergsagel P.L., Paul H., et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 2011, 29:1175-1181.
21. Sher T., Miller K.C., Lawrence D., et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010, 51:85-88.
22. Kotla V., Goel S., Nischal S., et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009, 2:36.
23. Dredge K., Horsfall R., Robinson S.P., et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic invivo and inhibits endothelial cell migration and Akt phosphorylation invitro. Microvasc Res 2005, 69:56-63.
24. Lu L., Payvandi F., Wu L., et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009, 77:78-86.
25. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
26. Rigolin G.M., Mauro E., Ciccone M., et al. Neoplastic circulating endothelial-like cells in patients with acute myeloid leukaemia. Eur J Haematol 2007, 78:365-373.
27. Sylvan S.E., Rossmann E., Mozaffari F., et al. Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression. Br J Haematol 2012, 159:608-612.
28. Brown J.R., Abramson J., Hochberg E., et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia 2010, 24:1972-1975.
29. McDaniel J.M., Pinilla-Ibarz J., Epling-Burnette P.K. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol 2012, 2012:513702.
30. Schulz A., Durr C., Zenz T., et al. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary co-cultures by altering the myeloid microenvironment. Blood 2013, 121:2503-2511.
31. Reddy N., Hernandez-Ilizaliturri F.J., Deeb G., et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab invivo. Br J Haematol 2008, 140:36-45.
32. Buesche G., Dieck S., Giagounidis A., et al. Anti-angiogenic invivo effect of lenalidomide (CC-5013) in myelodysplastic syndrome with del(5q) chromosome abnormality and its relation to the course of disease. Blood 2005, 106:113a.
33. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Nat Acad Sci U S A 1994, 91:4082-4085.
34. Dispenzieri A., Klein C.J., Mauermann M.L. Lenalidomide therapy in a patient with POEMS syndrome. Blood 2007, 110:1075-1076.
35. Sargiannidou I., Zhou J., Tuszynski G.P. The role of thrombospondin-1 in tumor progression. Exp Biol Med (Maywood) 2001, 226:726-733.
36. Strydom D.J. The angiogenins. Cellular and molecular life sciences: CMLS 1998, 54:811-824.
37. Rossi D., Bruscaggin A., Spina V., et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association withprogression and fludarabine-refractoriness. Blood 2011, 118:6904-6908.
38. Molica S., Vitelli G., Levato D., et al. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression. Eur J Haematol 2004, 73:36-42.
39. Verstovsek S., Kantarjian H., Aguayo A., et al. Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol 2001, 114:290-295.
40. Montero S., Guzman C., Cortes-Funes H., Colomer R. Angiogenin expression and prognosis in primary breast carcinoma. Clin Cancer Res 1998, 4:2161-2168.
41. Agliano A., Martin-Padura I., Marighetti P., et al. Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res 2011, 17:6163-6173.
42. Li H., Raia V., Bertolini F., Price D.K., Figg W.D. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU Int 2008, 101:884-888.
43. Rigolin G.M., Maffei R., Rizzotto L., et al. Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biologic significance. Cancer 2010, 116:1926-1937.
44. Gora-Tybor J., Jamroziak K., Szmigielska-Kaplon A., et al. Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009, 50:62-67.
45. Kraan J., Sleijfer S., Foekens J.A., Gratama J.W. Clinical value of circulating endothelial cell detection in oncology. Drug Discov Today 2012, 17:710-717.
46. De Luisi A., Ferrucci A., Coluccia A.M., et al. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res 2011, 17:1935-1946.
47. Lebrin F., Srun S., Raymond K., et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010, 16:420-428.
48. Wobus M., Benath G., Ferrer R.A., et al. Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. Exp Hematol 2012, 40:867-876.
49. Gupta D., Treon S.P., Shima Y., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15:1950-1961.
50. Badoux X., Bueso-Ramos C., Harris D., et al. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol 2011, 42:1989-2000.